Glucocorticoids exert their therapeutic effects by broadly suppressing the activity of immune cells, thereby increasing the risk of infection. Although this risk is dose-dependent, a clinically meaningful increase in infection risk persists even at daily doses lower than 5 mg of prednisone equivalent. We herein report the first documented case of a patient who developed concurrent crusted scabies and Candida albicans infection following glucocorticoid therapy for bullous pemphigoid.
Ye et al. (Mon,) studied this question.